Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast

Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights.

"We are delighted to share clinical data and business updates across several programs demonstrating that Sangamo has three important assets progressing toward late-stage development. Our gene therapy portfolio is advancing with accumulating safety and efficacy data in our Fabry and hemophilia A programs, and preliminary proof-of-concept data demonstrate the clinical potential of our zinc finger genome engineering technology in sickle cell disease. These data readouts show the progression of our first-generation genomic medicine pipeline and potentially pave the way for new treatments. Our next generation programs focus on genome regulation and allogeneic CAR-Treg cell therapy, where we have a robust preclinical pipeline in neurological and autoimmune diseases. We are energized by this momentum and look forward to continued execution of our corporate strategy," said Sandy Macrae, Chief Executive Officer of Sangamo.

Recent Clinical and Business Highlights

Fabry Disease ? First four patients dosed exhibited above normal ?-Gal A activity; Phase 3 planning initiated

Sickle Cell Disease ? Preliminary-proof-of-concept data will be presented at ASH as clinical program advances

Hemophilia A ? Four patients at highest dose experienced mean FVIII activity of 30.9% at week 104

Renal Transplant ? First patient enrolled, expect two patients to be dosed by mid-2022

Research, Manufacturing, and Corporate Updates

Third Quarter 2021 Financial Results

Consolidated net loss attributable to Sangamo for the third quarter ended September 30, 2021 was $47.7 million, or $0.33 per share, compared to a net loss attributable to Sangamo of $1.6 million, or $0.01 per share, for the same period in 2020.

Revenues

Revenues for the third quarter ended September 30, 2021, were $28.6 million, compared to $57.8 million for the same period in 2020, a decrease of $29.2 million.

The reduction in revenue was primarily due to a $39.3 million decrease related to our giroctocogene fitelparvovec and C9ORF72 collaboration agreements with Pfizer, resulting from the completion of our activities in 2020, and a $2.3 million decrease related to our collaboration agreement with Sanofi. These decreases were partially offset by higher revenues of $11.5 million and $1.3 million related to our collaboration agreements with Novartis and Biogen, respectively.

GAAP and Non-GAAP operating expenses

Three Months Ended
September 30,
Nine Months Ended
September 30,
(In millions)

2021

2020

2021

2020

 
Research and development

$

62.5

 

$

45.3

 

$

179.0

 

$

128.3

 

General and administrative

 

14.5

 

 

16.2

 

 

47.1

 

 

50.2

 

Total operating expenses

 

77.0

 

 

61.5

 

 

226.1

 

 

178.5

 

Stock-based compensation expense

 

(7.9

)

 

(6.7

)

 

(24.9

)

 

(19.1

)

Non-GAAP operating expenses

$

69.1

 

$

54.8

 

$

201.2

 

$

159.4

 

Total operating expenses on a GAAP basis for the third quarter ended September 30, 2021 were $77.0 million compared to $61.5 million for the same period in 2020. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the third quarter ended September 30, 2021 were $69.1 million compared to $54.8 million for the same period in 2020.

The increase in total operating expenses on a GAAP basis was primarily driven by our higher clinical and manufacturing supply expenses along with our increased headcount to support the advancement of our clinical trials and our ongoing collaborations.

Cash, cash equivalents and marketable securities

Cash, cash equivalents and marketable securities as of September 30, 2021 were $519.0 million compared to $692.0 million as of December 31, 2020.

Revised Financial Guidance for 2021

We are revising our full-year operating expense guidance initially provided on February 24, 2021 and reiterated most recently on August 5, 2021 as follows:

(in millions) Initially Provided February 24, 2021;
Reiterated May 4, 2021
and August 5, 2021
Updated on November 4, 2021
 
Estimated GAAP Operating Expenses

$285 to $305

$300 to $310

 
Estimated Non-GAAP Operating Expenses

$255 to $275*

$265 to $275**

*excludes estimated stock-based compensation of $30 million
**excludes estimated stock-based compensation of $35 million

Conference Call

Sangamo will host a conference call today, November 4, 2021, at 9:15 a.m. Eastern Time, which will be open to the public. The call and live Q&A will be webcast.

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 5178059. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 5178059.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don't exist. For more information about Sangamo, visit www.sangamo.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, the anticipated advancement of our product candidates to late-stage development including potential future Phase 3 trials, anticipated implementation of a protocol amendment for the Phase 3 AFFINE clinical trial of giroctocogene fitelparvovec and the resumption of the dosing of additional patients in the trial; our revised 2021 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation; our continued execution of our corporate strategy; the anticipated completion of our in-house cell therapy manufacturing facility in Valbonne, France; and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the uncertain timing and unpredictable nature of clinical trials and clinical trial results, including the risk that any protocol amendment for the Phase 3 AFFINE trial of giroctocogene fitelparvovec may not be accepted by the relevant review bodies in a timely manner, or at all, or that the FDA may not lift its clinical hold on the Phase 3 AFFINE trial in a timely manner, or at all, each of which could further delay or preclude further patient dosing in the trial as well as the risks that therapeutic effects observed in clinical trial results will not be durable in patients and that final clinical trial data will not validate the safety and efficacy of our product candidates; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; and our ability to achieve expected future financial performance.

There can be no assurance that we and our collaborators will be able to develop commercially viable products. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2020 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law.

Non-GAAP Financial Measure

To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business.

SELECTED CONSOLIDATED FINANCIAL DATA
(unaudited; in thousands, except per share data)
 
 
Statement of Operations Data:
Three months ended Nine Months Ended
September 30, September 30,

2021

2020

2021

2020

 
Revenues

$

28,563

 

$

57,763

 

$

82,715

 

$

92,392

 

Operating expenses:
Research and development

 

62,498

 

 

45,287

 

 

179,018

 

 

128,289

 

General and administrative

 

14,501

 

 

16,177

 

 

47,135

 

 

50,223

 

Total operating expenses

 

76,999

 

 

61,464

 

 

226,153

 

 

178,512

 

Loss from operations

 

(48,436

)

 

(3,701

)

 

(143,438

)

 

(86,120

)

Interest and other income, net

 

834

 

 

2,430

 

 

3,010

 

 

5,910

 

Loss before taxes

 

(47,602

)

 

(1,271

)

 

(140,428

)

 

(80,210

)

Income tax expense

 

86

 

 

237

 

 

373

 

 

237

 

Net loss

$

(47,688

)

$

(1,508

)

$

(140,801

)

$

(80,447

)

Net income (loss) attributable to non-controlling interest

 

-

 

 

42

 

 

(11

)

 

(55

)

Net loss attributable to Sangamo Therapeutics, Inc. stockholders

$

(47,688

)

$

(1,550

)

$

(140,790

)

$

(80,392

)

Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders

$

(0.33

)

$

(0.01

)

$

(0.98

)

$

(0.61

)

Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders

 

145,399

 

 

141,100

 

 

144,173

 

 

132,079

 

 
 
 
Selected Balance Sheet Data:
September 30, 2021 December 31, 2020
 
Cash, cash equivalents and marketable securities

$

519,044

 

$

691,953

 

Total assets

$

772,398

 

$

938,550

 

Total stockholders' equity

$

406,016

 

$

497,366

 

 


These press releases may also interest you

at 09:00
Transcat, Inc. ("Transcat" or the "Company"), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professional grade handheld test, measurement and control...

at 09:00
The "2022 BioPharma eMarketing Summit" conference has been added to ResearchAndMarkets.com's offering. Healthcare marketing has changed beyond all recognition. In a world of reduced access, how can marketers capitalize on this significant digital...

at 08:59
Nestlé Health Science, a globally recognized leader in the field of nutritional science, shared the publication of the results of a clinical trial in JAMA Network Open, a member of the JAMA Network, evaluating Mitopure Urolithin A (Mitopure). The...

at 08:59
Chronicled, the technology company behind MediLedger Network, has entered into a partnership with Parity Technologies, the developer behind Polkadot and Substrate; together the two will leverage modern peer-to-peer communication and blockchain...

at 08:55
The "Direct-to-Consumer Laboratory Testing Market - Middle East & Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering. This report studies the past as well as...

at 08:55
Medivir AB  today announces that an e-poster entitled "Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver" will be presented at the European Association for the Study of the Liver...



News published on 4 november 2021 at 09:20 and distributed by: